A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment(ESCALADE)
Sponsor: Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies)
Listed as NCT05041790, this PHASE4 trial focuses on Mild Cognitive Impairment and remains ongoing. Sponsored by Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies), it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Jan 2025 — Sep 2025 [monthly]
Unknown PHASE4
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE4
-
Oct 2021 — Jul 2024 [monthly]
Not Yet Recruiting PHASE4
First recorded
Sep 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies)
- Chong Kun Dang Pharmaceutical
For direct contact, visit the study record on ClinicalTrials.gov .